argenx SE ARGNF
900.30 USD 0.00 (+0.00%)
At closeNov 10, 2026, 4:00 PM EST
995.00 Day range 995.00
712.03 52-week range 1,020.00
- YTD
- +3.48%
- 1 year
- +7.18%
News
fool.com argenx: 3 Key Takeaways for Long-Term Investors Product net sales reached $1.7 billion, growing 54% year over year. Operating profit reached $486 million with a 28% operating margin.
businesswire.com Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium BOSTON--(BUSINESS WIRE)--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium.
businesswire.com BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology…
wsj.com Argenx to Buy Forte Biosciences for $2.2 Billion The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.
reuters.com Argenx to buy Forte Biosciences for about $2.2 billion Belgian-Dutch immunology company argenx will buy Forte Biosciences to add experimental autoimmune drug FB102 to its portfolio, the company said on Monday.
reuters.com Argenx's Vyvgart sales jump in second quarter Belgian-Dutch immunology company argenx said on Thursday global sales of its lead drug Vyvgart jumped in the second quarter of 2026 from a year earlier.
investors.com Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.
seekingalpha.com argenx SE (ARGX) Q1 2026 Earnings Call Transcript argenx SE (ARGX) Q1 2026 Earnings Call Transcript